Sunmary Urinary ql excretion is independent of the main indices of tumour activity in myelomatosis (serum paraprotein, serum ,B2-microglobulin, serum creatinine and urinary light chain production). The mean (±s.d.) at presentation was 40.7 + 22.6 nmol . ,umol ucr 1, compared to 25.4 + 4.8 nmol . gmol ucr-in controls. Urinary levels at presentation are significantly related to prognosis, the higher the level the poorer the prognosis. However, when these levels have been stratified according to the corresponding level of serum /B2 m, the level adds little as a prognostic factor.
Several biochemical indices have been found to be valuable as guides to prognosis in myelomatosis, they include serum creatinine, paraprotein urinary free light chain excretion and haemoglobin levels (Durie & Salmon, 1975) . More recently the serum f2-microglobulin level has been confirmed to be a powerful prognostic indicator (Child et al., 1983; Bataille et al., 1984 , Cuzick et al., 1985 . Nevertheless, the variation of the course of the disease within the subsets defined by combinations of these indicators warrants further study to try to improve our predictions at the individual patient level.
There is growing evidence that the increased urinary excretion of modified nucleosides is a common feature of many types of advanced cancers including lymphomas (Salvatore et al., 1983; Rasmunson et al., 1983) . The modified nucleosides are produced by post-transcriptional enzymatic action; tRNA contains the highest and most varied number of modified nucleosides. No retrieval pathway exists for these compounds, ensuring that they are not randomly inserted into the macromolecules (Borek, 1983; Dirheimer, 1983) . The catabolites of tRNA are excreted into the urine without reabsorption and consist of pseudouridine (i/) and possibly as many as 50 methylated nucleosides. Pseudouridine is generally excreted in concentrations of 10 to 100 times that of other modified nucleosides both in healthy subjects and cancer patients. There are previous reports indicating that l excretion levels tends to carry as much information in terms of its relation to tumour mass and activity as a formal analysis of the spectrum of modified nucleosides (Rasmunson et al., 1983) ; but others favour the simultaneous analysis of several nucleosides Heldman et al., 1983) .
In this paper we report the levels of urninary / excretion in myelomatosis, determine its role as a prognostic indicator alone, and investigate whether it can add information once the patients have been stratified for serum f2m levels.
Materials and methods

Patients
The 264 patients were all entered into the Medical The urinary nucleosides were first isolated by affinity chromatography on boronate Affi-gel 667 obtained from Bioard (Watford, UK), as described by Gehrke et al. (1978) . Pseudouridine was then assayed by reverse phase chromatography on a 300 x 5 mm Spherisorb 5 ODS column in conjunction with an Applied Chromatography Systems HPLC apparatus, and the absorbance monitored at 254 nm, 0.1 AUFS, 20 M1 of reconstituted nucleosides (equiv. to lOpl of urine) was injected on to the column. The i peak was isocraticly eluted by 10mM ammonium phosphate buffer, pH5.1, containing 5% methanol, during the first 4min of the chromatogram. The flow rate was 1 ml min-1 at a pressure of 2000 psi. The rest of the nucleosides were then batch eluted by raising the methanol content to 50% in one step, and after 3min the column was re-equilibrated for the next run. The peak heights were measured and compared to a range of u/ standards. The q/ concentration in urine is given as nmol.umol urinary creatinine-(ucr).
C The Macmillan Press Ltd., 1985 The serum ,B2m was assayed by radial immunodiffusion using antisera obtained from Dako, (Copenhagen, Denmark), the myeloma serum paraproteins and urinary free light chain were assayed in the Department of Immunology, University of Birmingham as previously described (Medical Research Council, 1984) , and the urinary creatinine determined by the Jaffe reaction.
Survival curves were drawn for subgroups of patients defined by their f2m or i levels using the method of Kaplan and Meier (1958) . The statistical significance of differences in the survival distribution between the sub-groups was tested using the logrank test (Peto et al., 1977) before and after covariate adjustment.
Results
The / assay including the isolation step was highly reproducible, it gave a mean recovery of 96+6% of a 0.307 nmol 1-' solution in 20 replicate measurements.
The mean (+ s.d.) level of urinary / of 25.5 +4.8 nmol.iimol ucr-' in the controls is comparable to other published results (Salvatore et al., 1983; Rasmunson et al., 1983; Borek et al., 1983) . There was no evidence for a correlation between the q/ excretion and the age or surface area in the control group.
A survey of the urinary / levels in myeloma patients at presentation showed that the mean (± s.d.) of 40.7 + 22.6 nmol . pmol ucr'-is highly significantly increased compared to that of the controls Z=9.26 (P<0.001).
A correlation matrix was computed to examine the correlation coefficients of urinary t excretion levels with the main biochemical indices of tumour activity in myelomatosis. Figure 1 . There is a highly significant linear trend for prognosis to become worse with a rising level of urinary t, Chi square for trend (1 df)=9.85; P=0.0017. The corresponding survival curves for the patients stratified according to their serum /32m levels at presentation are shown in Figure 2 . The strong prognostic effect of this parameter is apparent, the Chi square for trend, 31.15, is highly significant (P= <0.00001). It will be seen that the majority of early deaths occurred in patients with a serum 32m>8mgl-'.
The statistical significance of the presentation level of urinary on survival after stratification for serum fl2m level is shown in Table I . It can be seen that after serum fl2m levels are taken into account urinary level is no longer a significant prognostic factor. Conversely after adjusting the prognostic significance for the level of urinary level the Chi square for trend remains at 22.5 (P=0.00001).
Discussion
An increased urinary excretion of modified nucleosides, including tl occurs in a wide spectrum of cancers, see Borek (1983) for a comprehensive review. Haematological neoplasms including acute leukaemias in children (Heldman et al., 1983b) and adults (Heldman et al., 1983a; Nielsen & Killman, 1983) as well as chronic granulocytic leukaemia (Nielsen & Killman et al., 1983; Heldman et al., 1983c) (Heldman et al., 1983a) .
There are reports of age dependent changes in modified nucleoside excretion including (Tritsch et al., 1979) . In children the levels decrease linearly with age from birth to 16 years old (Heldman et al., 1983b) . Conversely the mean levels of excretion were reported as 12.9 nmol . pmol ucr-creatinine at age 25 and 38.4 nmol. pmol ucr -at age 90 rising by 5.9 nmol. pmol cr -1 per decade (Tritsch et al., 1979 at presentation is of prognostic significance, but adds little prognostic information to that contained in the serum fl2m level. This study once again reinforcing the opinion that serum f2m level an extremely powerful prognostic factor in myelomatosis. (Cuzick et al., 1985) . Thomale and Nass (1983) have suggested that modified nucleoside excretion in cancer results from a combination of intrinsic alterations in enzymatic activity and secondary events resulting from the overall metabolism of the host as the tumour grows. The results of the present study could be explained by a similar hypothesis. Preliminary studies of the spectrum of methylated nucleosides excreted in myelomatosis indicate that a high level of q excretion is associated with an increased excretion of several methylated nucleosides, and is not an isolated event (S0rensen, unpublished data).
In this context it is of interest that indicators of protein synthetic activity of the tumour (serum paraprotein level and urinary light chain excretion) are not correlated with urinary & excretion. This favours the concept that the urinary i is a reflection of the tumour mass and the probable increase of divergence of tRNA metabolism away from normal with increasing cytogenetic aberration within the tumour cell line. 
